Nanatinostat
As of the edition of 20 October 2026, Nanatinostat is a small molecule: stopped in 2025; acts on HDAC1, HDAC2 and HDAC3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 4, 3 stopped early
- Disease areas
- Cancer; Digestive system; Ear, nose and throat; Infections; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Nanatinostat.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chroma Therapeutics | Lead sponsor of trials | 2008 to now |
| Viracta Therapeutics | Lead sponsor of trials | 2021 to now |